New drug INCA035784 enters human testing for rare blood cancers
NCT ID NCT07008118
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 33 times
Summary
This early-stage trial tests a new drug, INCA035784, in 120 adults with myeloproliferative neoplasms (a group of blood cancers). The main goal is to check safety and find the right dose. Participants must have a specific genetic mutation (CALR) and have tried other treatments before.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Azienda Ospedaliero Universitaria Careggi-S.O.D. Patologia Medica
NOT_YET_RECRUITINGFlorence, 50134, Italy
-
Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii
NOT_YET_RECRUITINGBergamo, 24127, Italy
-
Centro Ricerche Cliniche Di Verona
NOT_YET_RECRUITINGVerona, 37134, Italy
-
Cliniques Universitaires Saint-Luc
NOT_YET_RECRUITINGBrussels, 01200, Belgium
-
Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
-
Fondazione Irccs Ca Granda Ospedale Maggiore
NOT_YET_RECRUITINGMilan, 20122, Italy
-
Huntsman Cancer Institute At University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Icahn School of Medicine At Mount Sinai
RECRUITINGNew York, New York, 10029, United States
-
Johns Hopkins University
NOT_YET_RECRUITINGBaltimore, Maryland, 21287, United States
-
Linear Clinical Research
RECRUITINGNedlands, Western Australia, 06009, Australia
-
Macquarie University Hospital
RECRUITINGSydney, New South Wales, 02109, Australia
-
Mayo Clinic Hospital
NOT_YET_RECRUITINGPhoenix, Arizona, 85054, United States
-
Mayo Clinic-Florida
NOT_YET_RECRUITINGJacksonville, Florida, 32224, United States
-
Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
-
Royal Adelaide Hospital
RECRUITINGAdelaide, South Australia, 05000, Australia
-
South Austin Medical Center
RECRUITINGAustin, Texas, 78704, United States
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
-
The Alfred Hospital
RECRUITINGMelbourne, Victoria, 03004, Australia
-
Universitaetsklinikum Dresden
NOT_YET_RECRUITINGDresden, 01307, Germany
-
Universitair Ziekenhuis Gent
NOT_YET_RECRUITINGGhent, 09000, Belgium
-
Universitaire Ziekenhuizen Leuven
NOT_YET_RECRUITINGLeuven, 03000, Belgium
-
Universitatsklinikum Halle (Saale)
NOT_YET_RECRUITINGHalle, 06120, Germany
-
Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
NOT_YET_RECRUITINGMainz, 55131, Germany
-
University of Chicago Medical Center
NOT_YET_RECRUITINGChicago, Illinois, 60637, United States
-
University of North Carolina At Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27514, United States
-
University of Texas Southwestern Medical Center Harold C Simmons Comprehensive Cancer Center Blood
NOT_YET_RECRUITINGDallas, Texas, 75235, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INCA035784
What this could lead to
If successful, this could point toward a new treatment option for certain blood cancers called myeloproliferative neoplasms.
What could go wrong
This is an early Phase 1 trial focused on safety, not effectiveness. It is small and may not lead to a working treatment. Side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.